EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

Pharmacokinetics and 180‐day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2–5 years

Eric B Segal iD, James W Wheless iD, Muhammad Zafar iD, Evelyn K Shih iD, Leock Y Ngo iD, Enrique Carrazana iD, Adrian L Rabinowicz iD, DIAZ.001.008 Study Group

Epilepsia · 2025

DOI: 10.1111/epi.18473 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Epilepsia, 2025. Verfasst von Eric B Segal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hackensack University Medical Center, Northeast Regional Epilepsy Group, and Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA. Hauptthemen laut MEDLINE: Diazepam, Anticonvulsants, Epilepsy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Neurelis, Inc, Neurelis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Benzodiazepine immediate‐use seizure medications (ISMs; also called rescue therapies) are used to treat seizure clusters/acute repetitive seizures in patients with epilepsy. In the United States, diazepam nasal spray is an approved ISM for patients ≥2 years of age. The primary objective was to assess diazepam nasal spray pharmacokinetics (PK) in patients 2–5 years of age; safety and tolerability were secondary objectives.

Methods

This Phase 1/2a, open‐label, single‐dose, PK study with a 180‐day open‐label safety period enrolled patients with epilepsy 2–5 years of age. Diazepam nasal spray (0.5‐mg/kg per diazepam rectal gel dosing) was administered by a medical professional, followed by PK sampling. During the safety period, caregivers administered diazepam nasal spray as needed for frequent or acute repetitive seizures. Seizures and dosing were recorded in a diary. Study visits included safety evaluations. Use of second doses was a proxy for effectiveness.

Results

Thirty‐six patients were enrolled, with 35 in the PK population. PK parameters and modeling were comparable to older children and adults, confirming that diazepam nasal spray was readily absorbed and supporting the adequacy of the 0.5‐mg/kg dose for this age group. In the open‐label period, second doses within 24 h of the initial dose were administered for 16.3% of seizure events (37/227), indicating that a second dose was not used for most seizure events (83.7%). Treatment‐related treatment‐emergent adverse events occurred in seven patients (19.4%); all were mild except one (moderate). There was one report each of respiratory depression and respiratory distress; neither was treatment related. Significance This study characterizes the PK of diazepam in patients 2–5 years of age and reports a safety profile consistent with older patients. Results demonstrate that the diazepam nasal spray drug–device combination is appropriate for drug delivery and absorption in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DiazepamAnticonvulsantsEpilepsyHumansMaleChild, PreschoolFemaleNasal SpraysAdministration, Intranasal

Stichwörter der Autor:innen

diazepamintranasalpediatricrescue medicationseizure clusters

Substanzen

DiazepamNasal SpraysAnticonvulsants

Autor:innen und Institutionen

  • Hackensack University Medical Center, Northeast Regional Epilepsy Group, and Hackensack Meridian School of Medicine, Hackensack, New Jersey, USA.
  • Le Bonheur Children's Hospital, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Duke University School of Medicine, Durham, North Carolina, USA.
  • Formerly of Neurelis, Inc., San Diego, California, USA.
  • Neurelis, Inc., San Diego, California, USA.
  • John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.

ORCID-Profile: Eric B Segal, James W Wheless, Muhammad Zafar, Evelyn K Shih, Leock Y Ngo, Enrique Carrazana, Adrian L Rabinowicz

Förderung

  • Neurelis, Inc
  • Neurelis

Zitieren

APA

Segal, E. B., Wheless, J. W., Zafar, M., Shih, E. K., Ngo, L. Y., Carrazana, E., Rabinowicz, A. L., & DIAZ.001.008 Study Group (2025). Pharmacokinetics and 180‐day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2–5 years. Epilepsia. https://doi.org/10.1111/epi.18473

Vancouver

Segal EB, Wheless JW, Zafar M, Shih EK, Ngo LY, Carrazana E, et al. Pharmacokinetics and 180‐day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2–5 years. Epilepsia. 2025. doi:10.1111/epi.18473

BibTeX
@article{Segal2025,
  author = {Segal, Eric B and Wheless, James W and Zafar, Muhammad and Shih, Evelyn K and Ngo, Leock Y and Carrazana, Enrique and Rabinowicz, Adrian L and DIAZ.001.008 Study Group, DIAZ.001.008 Study Group},
  title = {Pharmacokinetics and 180‐day safety of diazepam nasal spray in pediatric patients with epilepsy aged 2–5 years},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18473}
}
Kostenlos starten →